Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized Phase 3 trial - Roth, E M; Taskinen, M R; Ginsberg, H N (Int J Cardiol, 2014)
et al.